Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements ...
A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...
A new study from North Carolina State University found that neutrophils—white blood cells that are a key part of the immune ...
Galderma’s Nemluvio (nemolizumab) has shown rapid relief of itch, as well as improvement in sleep, in patients with atopic ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
A narrative review highlights flexible abrocitinib treatment for moderate-to-severe atopic dermatitis, emphasizing lowest ...
Atopic dermatitis, which is known as eczema, is a skin condition that irritates, inflames, and interrupts your everyday life. It comes with symptoms like dryness, itching, redness, and flareups.
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback